Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
4,440,602
-
Number of holders
-
7
-
Total 13F shares, excl. options
-
70,777
-
Shares change
-
+53,317
-
Total reported value, excl. options
-
$81,774
-
Value change
-
+$68,070
-
Number of buys
-
6
-
Number of sells
-
-1
-
Price
-
$1.16
Significant Holders of Virax Biolabs Group Ltd - Ordinary Shares (VRAX) as of Q2 2024
8 filings reported holding VRAX - Virax Biolabs Group Ltd - Ordinary Shares as of Q2 2024.
Virax Biolabs Group Ltd - Ordinary Shares (VRAX) has 7 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 70,777 shares
of 4,440,602 outstanding shares and own 1.6% of the company stock.
Largest 8 shareholders include Virtu Financial LLC (28,058 shares), HRT FINANCIAL LP (25,672 shares), RENAISSANCE TECHNOLOGIES LLC (11,001 shares), UBS Group AG (5,601 shares), Qube Research & Technologies Ltd (300 shares), WELLS FARGO & COMPANY/MN (100 shares), Headlands Technologies LLC (45 shares), and CITADEL ADVISORS LLC (0 shares).
This table shows the top 7 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.